-
NEWS: US FDA approves Narcan (4mg naloxone nasal spray) for over-the-counter purchase/use
(From the US FDA press release) Today, the U.S. Food and Drug Administration approved Narcan, 4 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription, use – the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose. Today’s action paves the way for the life-saving medication to reverse an opioid overdose to be sold directly to consumers in places like drug stores, convenience stores, grocery stores and gas stations, as well as online. Read the complete press release. Posted March 29, 2023
-
Protocol Update: CTN-0139
March 15, 2023 CTN-0139, the Collaborative Care for Polysubstance use in Primary Care Settings (Co-Care) Trial, is studying a collaborative care intervention for polysubstance use involving opioids and/or stimulants, in adult primary care patients. Collaborative care is a team-based approach to managing chronic conditions that has been effective for depression and other behavioral health conditions, and has the potential to transform the delivery of substance use treatment in primary care settings. This HEAL-funded CTN trial will test the Co-Care model versus enhanced usual care to reduce substance use and improve substance use-related functioning. The study will be conducted at 5 primary care sites (FQHCs and FQHC look-alikes). A pilot study…
-
Recording Available: Cultural Considerations for Addiction Research: Looking to the Past to Inform the Future
The Office of Research Training, Diversity, and Disparities is offering a series titled Profiles of Excellence: Focus on Diversity. This webinar, held on March 6, 2023 from 4-5pm EST, featured Ayana Jordan, MD, PhD, of NYU Grossman School of Medicine, talking about “Cultural Considerations for Addiction Research: Looking to the Past to Inform the Future.” View the recording here. (Passcode: Yyr!6b?j)
-
Webinar: Injectable XR Buprenorphine: A Better Mousetrap or a Paradigm Shift in MOUD (April 6, Northeast Node)
Join the CTN Northeast Node on April 6, 2023 (12pm-1pm ET) for the latest in their Science Series: Injectable XR Buprenorphine: A Better Mousetrap or a Paradigm Shift in MOUD? with Eva Quirion, NP, PhD This presentation will explore the science behind extended release (XR) buprenorphine and field experiences in the use of XR buprenorphine in a primary care setting. This talk will also address ways to bring this medication to patients and if this treatment makes financial sense. 1.0 AMA PRA Category 1 CME available! Join the Zoom meeting here (no registration necessary)
-
REGISTER NOW! CTN Annual Steering Committee Meeting: April 24-26, 2023
March 2, 2023 Registration is now open for this year’s CTN Annual Steering Committee Meeting, April 24-26, 2023! The 2023 CTN Annual Steering Committee Meeting is being held in-person at the Bethesda North Marriott Hotel and Conference Center (book your reservation here!) in Rockville, Maryland, from April 24–26, 2023. For those unable to attend in person, all plenary sessions and some ancillary sessions will be broadcast via Zoom. The level of interaction available virtually will vary by session. Both in-person and virtual attendees will register on the Zoom Events platform: Both methods will give you the same virtual experience and will not affect in-person attendance! The “Information” tab includes hotel, travel, agenda…
